GO:0008287 protein serine/threonine phosphatase complex: Components, Assembly and Research Methods, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0008287 describes a cellular component: a protein complex that removes phosphate groups from serine or threonine residues on target proteins.
• These complexes are typically built from a catalytic subunit plus one or more regulatory or scaffold subunits that control substrate selection and location.
• The catalytic reaction is metal-dependent hydrolysis of a phosphoester bond, releasing inorganic phosphate and resetting the phosphorylation state of the substrate.
• Protein serine/threonine phosphatase complexes control cell division, autophagy, metabolic signaling and cell death pathways such as PANoptosis [3,5,6].
• Dysregulation of these complexes is linked to cancer, metabolic dysfunction-associated steatohepatitis and inflammatory cell death [1,3,7].
• CRISPR knockout, point-mutation, knock-in and overexpression models are the main tools for assigning causal roles to individual phosphatase subunits [1,3,5].
Description
GO:0008287, protein serine/threonine phosphatase complex, is a Gene Ontology cellular component term that defines a multi-subunit assembly whose job is to remove phosphate groups from serine or threonine residues of target proteins. Phosphorylation is one of the most common post-translational modifications in eukaryotic cells, and the enzymes that reverse it are as important as the kinases that add it. The QuickGO definition emphasizes that these complexes normally contain a catalytic subunit and a regulatory subunit, which together determine where, when and on which substrate the phosphatase acts. For researchers, GO:0008287 is therefore not a single protein but a functional module: the catalytic subunit performs chemistry, while regulatory and scaffold subunits provide specificity, targeting and stimulus-dependent control. This modularity explains why the same catalytic family can participate in very different processes, from mitotic progression to autophagy and inflammatory cell death [3,5,6]. Understanding the composition and regulation of protein serine/threonine phosphatase complexes is essential for interpreting phosphoproteomic data, designing kinase/phosphatase-directed therapeutics and building faithful cell models. Because these complexes are druggable and frequently altered in disease, they are a recurring target of CRISPR-based functional genomics [1,3,8].
protein serine/threonine phosphatase complex At A Glance
| GO ID | GO:0008287 |
|---|---|
| GO term | protein serine/threonine phosphatase complex |
| Ontology | cellular_component |
| Synonym | None listed in QuickGO |
| Major function | Catalyzes removal of a phosphate group from a serine or threonine residue of a protein |
| Typical composition | A catalytic subunit plus a regulatory subunit, often with additional scaffold or targeting subunits |
| Catalytic chemistry | Metal-dependent hydrolysis of a phosphoester bond, releasing inorganic phosphate |
| Subcellular context | Cytosol, nucleus and organelle-associated pools depending on the regulatory subunit |
| Representative families | PP1, PP2A, PP4, PP6 and related serine/threonine-specific phosphoprotein phosphatases |
What Is GO:0008287?
In my own words, GO:0008287 (protein serine/threonine phosphatase complex) is a cellular component consisting of a protein assembly that catalyzes the removal of a phosphate group from a serine or threonine residue of a substrate protein. The QuickGO definition notes that such a complex normally consists of a catalytic and a regulatory subunit, meaning the holoenzyme is a composite machine rather than a single polypeptide. The catalytic subunit carries the phosphoesterase active site, while the regulatory subunit modulates activity, substrate recognition or subcellular targeting. Because the term is a cellular component, it describes where the activity resides in the cell rather than the activity itself.
Why Is protein serine/threonine phosphatase complex Important in Cell Biology?
Protein serine/threonine phosphatase complexes are important because they set the off-switch for a large fraction of cellular phosphorylation events, and their subunit composition determines which pathways are switched off [2,4]. Without them, kinase-driven signals would be irreversible, and processes such as mitosis, autophagy and metabolic adaptation would lose their timing and reversibility [5,6]. Their disease relevance is broad: PP6-containing complexes have been linked to metabolic dysfunction-associated steatohepatitis through mTORC1 signaling, to RIPK1-dependent PANoptosis and to autophagy control via the Beclin 1/Vps34 complex. Because these complexes are enzyme machines with defined active sites and regulatory interfaces, they are also attractive drug targets. For researchers, GO:0008287 provides a controlled vocabulary for annotating which phosphatase holoenzyme is present in a given cell state, which is essential for reproducible phosphoproteomics and functional genomics.
• They reverse serine/threonine phosphorylation, making them core regulators of signal duration and amplitude.
• Their regulatory subunits determine substrate specificity, so the same catalytic subunit can serve distinct pathways.
• They control cell division and mitotic progression.
• They regulate autophagy by modulating complexes such as Beclin 1/Vps34.
• They participate in cell death decisions, including RIPK1-dependent PANoptosis.
• They influence metabolic signaling through pathways such as mTORC1.
• Their dysregulation has been associated with cancer progression and stress responses.
• They are validated or candidate drug targets for phosphatase-directed therapeutics.
• They are recurrent hits in phosphoproteomic and CRISPR functional screens [1,3].
• They provide a cellular-component annotation that helps interpret subcellular phosphoproteomics data.
What Happens During protein serine/threonine phosphatase complex?
Substrate recognition and docking
In simple terms: The phosphatase first has to grab the right protein before it can remove its phosphate.
A protein serine/threonine phosphatase complex does not act on every phosphoprotein at once; regulatory and scaffold subunits create docking surfaces that recruit specific substrates. This selectivity is what allows a limited number of catalytic subunits to control many pathways, and it is a major reason why the holoenzyme, not the isolated catalytic domain, is the biologically relevant unit. Loss of the regulatory subunit can therefore redirect or abolish phosphatase activity toward a given substrate without changing the catalytic subunit itself.
Catalytic dephosphorylation
In simple terms: Once the substrate is bound, the enzyme clips off the phosphate group.
The catalytic subunit hydrolyzes the phosphoester bond on a serine or threonine residue, releasing inorganic phosphate and restoring the unphosphorylated side chain. This reaction is metal-dependent and is the defining biochemical activity of the complex described by GO:0008287. Because the reaction is hydrolytic and essentially irreversible under cellular conditions, the phosphatase sets a directional off-switch for the modified site.
Signal termination and pathway resetting
In simple terms: Removing the phosphate turns the signal off so the cell can respond again.
Dephosphorylation terminates or resets kinase-driven signals, which is essential for reversible processes such as cell-cycle transitions and stress responses. In autophagy, PP6-containing complexes can dissociate the Beclin 1/Vps34 complex and thereby inhibit autophagy, illustrating how a phosphatase complex can dismantle a signaling platform rather than merely edit a single site. In cell death signaling, PP6 promotes RIPK1-dependent PANoptosis, showing that phosphatase complexes can also be required for execution of a death program.
Integration with metabolic and stress signaling
In simple terms: These enzymes also help the cell adjust its metabolism when nutrients or stress change.
Protein phosphatase 6 regulates metabolic dysfunction-associated steatohepatitis via the mTORC1 pathway, linking a serine/threonine phosphatase complex to nutrient-sensing and liver disease. Stress-induced signals can also intersect with phosphatase regulation, as shown by ROS-induced cytosolic release of mitochondrial PGAM5 interacting with MST3 in colorectal cancer progression. Together these examples show that GO:0008287 complexes are not passive housekeeping enzymes but active nodes in metabolic and stress signaling [1,7].
Key Genes Involved in GO:0008287 protein serine/threonine phosphatase complex
The following genes and proteins represent catalytic subunits, regulatory subunits and pathway partners that are experimentally connected to protein serine/threonine phosphatase complexes.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PPP6C | Catalytic subunit of protein phosphatase 6 | Central to PP6 holoenzymes studied in metabolism, autophagy and cell death [1,3,5] |
| PPP2CA | Catalytic subunit of protein phosphatase 2A | Model catalytic subunit for serine/threonine phosphatase complex biology [2,4] |
| PPP1CA | Catalytic subunit of protein phosphatase 1 | Prototype for catalytic/regulatory subunit pairing [2,4] |
| PPP4C | Catalytic subunit of protein phosphatase 4 | Illustrates family diversity among serine/threonine phosphatases |
| PPP2R1A | Scaffold/regulatory subunit of PP2A | Defines holoenzyme assembly and substrate targeting |
| PPP2R2A | Regulatory subunit of PP2A | Controls substrate selection and localization |
| PPP1R1A | Regulatory subunit of PP1 | Classic example of inhibitor/regulatory control |
| PPP6R1 | Regulatory subunit of PP6 | Modulates PP6 complex function [1,3] |
| PPP6R2 | Regulatory subunit of PP6 | Modulates PP6 complex function [1,3] |
| PPP6R3 | Regulatory subunit of PP6 | Modulates PP6 complex function [1,3] |
| BECN1 | Beclin 1, autophagy regulator | Target of PP6-mediated dissociation of the Beclin 1/Vps34 complex |
| PIK3C3 | Vps34, PI3K class III | Partner in the autophagy complex regulated by PP6 |
| RIPK1 | Cell death kinase/scaffold | PP6 promotes RIPK1-dependent PANoptosis |
| MTOR | mTOR kinase | mTORC1 pathway links PP6 to metabolic dysfunction-associated steatohepatitis |
| PGAM5 | Mitochondrial phosphatase | ROS-induced cytosolic release and interaction with MST3 in colorectal cancer |
| STK24 | MST3 kinase | Interacts with PGAM5 in colorectal cancer progression |
| PPP1R15A | Regulatory subunit of PP1 | Illustrates stress-responsive phosphatase regulation [2,4] |
How Is protein serine/threonine phosphatase complex Regulated?
Protein serine/threonine phosphatase complexes are regulated at multiple levels. First, regulatory and scaffold subunits determine substrate specificity and subcellular targeting, so expression changes in these subunits can redirect the holoenzyme without altering catalytic capacity. Second, post-translational modification and inhibitor proteins can tune catalytic activity, a principle well established for serine/threonine phosphatases. Third, upstream signaling pathways such as mTORC1 can influence phosphatase-complex function in metabolic contexts, as shown for PP6 in metabolic dysfunction-associated steatohepatitis. Fourth, stress signals can change the localization of phosphatase-related proteins, as illustrated by ROS-induced cytosolic release of mitochondrial PGAM5. Finally, phosphatase complexes can be regulated by their own substrates and interaction partners, including the Beclin 1/Vps34 complex in autophagy and RIPK1 in PANoptosis.
protein serine/threonine phosphatase complex and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PPP6C | Metabolic dysfunction-associated steatohepatitis via mTORC1 | Knockout and point-mutation hepatocyte models with metabolic stress readouts |
| PPP6C | RIPK1-dependent PANoptosis | Knockout cells challenged with cell-death inducers and PANoptosis markers |
| PPP6C | Autophagy inhibition via Beclin 1/Vps34 dissociation | Knockout plus autophagy flux reporters and co-immunoprecipitation |
| PGAM5 | Colorectal cancer progression under ROS stress | Overexpression and point-mutation models with oxidative stress challenge |
| PPP2CA / PPP2R1A | General serine/threonine phosphatase complex biology and drug targeting [2,8] | Knockout, knock-in and overexpression isogenic cell panels |
Metabolic liver disease
Protein phosphatase 6 regulates metabolic dysfunction-associated steatohepatitis via the mTORC1 pathway, indicating that PP6-containing serine/threonine phosphatase complexes are functionally involved in hepatic metabolic stress responses. This connection makes PP6 subunits candidate genes for metabolic liver disease models and for studies of nutrient-sensing signaling.
Inflammatory cell death and PANoptosis
The protein phosphatase PP6 promotes RIPK1-dependent PANoptosis, linking a serine/threonine phosphatase complex to inflammatory cell death execution. This finding expands the disease relevance of GO:0008287 beyond classical metabolism into inflammation and innate immune signaling.
Cancer progression and stress signaling
ROS-induced cytosolic release of mitochondrial PGAM5 promotes colorectal cancer progression by interacting with MST3, showing that phosphatase-related signaling can drive tumor phenotypes under oxidative stress. In addition, serine/threonine phosphatases have been reviewed as drug-development targets, underscoring their therapeutic relevance in cancer and other diseases.
Autophagy-related pathology
Protein phosphatase 6 dissociates the Beclin 1/Vps34 complex and inhibits autophagy, connecting GO:0008287 complexes to autophagy regulation, a process implicated in cancer, neurodegeneration and metabolic disease. This provides a mechanistic entry point for studying how phosphatase complexes shape autophagic flux in disease models.
From protein serine/threonine phosphatase complex-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is the catalytic subunit required for a signaling output? | CRISPR knockout of PPP6C or PPP2CA with phospho-substrate readouts [1,3] |
| Does a specific catalytic residue drive activity? | Point-mutation knock-in of the catalytic subunit active site [2,4] |
| Does a disease-associated variant alter complex function? | Knock-in of the variant allele into an isogenic background |
| Where and when is the complex assembled? | Tagged knock-in of catalytic or regulatory subunits for imaging and proteomics |
| Does excess phosphatase activity change phenotype? | Overexpression of catalytic plus regulatory subunits [5,7] |
| Which pathways depend on the holoenzyme? | CRISPR library screening in knockout or point-mutant backgrounds |
How to Study the protein serine/threonine phosphatase complex Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Phosphoproteomics | Phosphorylation state of serine/threonine sites | Detect substrate changes after phosphatase perturbation [2,4] |
| Co-immunoprecipitation | Physical interactions among complex subunits | Define holoenzyme composition [4,5] |
| Affinity purification mass spectrometry | Protein interaction network of a bait subunit | Map regulatory and scaffold partners |
| Autophagy flux assay | Autophagic degradation and flux | Test PP6 effects on Beclin 1/Vps34 and autophagy |
| Cell-death panel | Apoptosis, necroptosis and PANoptosis markers | Test PP6-dependent RIPK1 signaling |
| CRISPR knockout screening | Gene requirement across a phenotype | Identify phosphatase subunits and modifiers |
| Live-cell imaging | Localization and dynamics of tagged subunits | Track complex assembly and substrate recruitment |
| Bioinformatic pathway enrichment | Overrepresented pathways in omics data | Interpret phosphoproteomic and transcriptomic hits [4,8] |
Phosphoproteomics
Mass-spectrometry-based phosphoproteomics measures the phosphorylation state of thousands of serine and threonine sites and is the most direct way to detect the consequences of altering a protein serine/threonine phosphatase complex [2,4]. Comparing knockout, point-mutant and wild-type cells reveals candidate substrate sites and pathways.
Co-immunoprecipitation and interaction proteomics
Because GO:0008287 defines a complex rather than a single protein, interaction methods are essential. Co-immunoprecipitation and affinity purification coupled to mass spectrometry identify catalytic, regulatory and scaffold subunits and reveal how complex composition changes across conditions [4,5].
Functional cell-death and autophagy assays
Autophagy flux reporters and cell-death panels can test whether a phosphatase complex promotes or inhibits a process, as shown for PP6 in autophagy and PANoptosis [3,5]. These assays convert molecular interaction data into pathway-level conclusions [3,5].
CRISPR functional genomics and bioinformatics
Pooled CRISPR screens combined with pathway enrichment and network analysis can identify which phosphatase subunits and downstream pathways are required in a given disease model. Bioinformatics integration of phosphoproteomic and transcriptomic data helps prioritize the most likely causal subunit [4,8].
How CRISPR Can Be Used to Study GO:0008287 protein serine/threonine phosphatase complex
Knockout
CRISPR knockout of catalytic or regulatory subunits is the standard first step to test whether a protein serine/threonine phosphatase complex is required for a phenotype. Knockout of PP6 subunits has been used to probe metabolic signaling, autophagy and PANoptosis [1,3,5]. Knockout models are also the foundation for downstream phosphoproteomic comparisons.
Point Mutation
Point-mutation models allow separation of catalytic activity from scaffolding or interaction functions. Introducing active-site mutations into the catalytic subunit can test whether dephosphorylation chemistry is required for a phenotype, a strategy grounded in the catalytic mechanism of serine/threonine phosphatases [2,4].
Knock-in
Knock-in of disease-associated variants or tagged alleles enables isogenic comparisons and live-cell tracking of the complex. Tagged knock-in of catalytic or regulatory subunits supports interaction proteomics and imaging of endogenous complexes. Variant knock-in can test whether a specific allele alters complex function in disease-relevant models.
Overexpression
Overexpression of catalytic and regulatory subunits together can test gain-of-function effects and pathway suppression. Overexpression approaches have been used to study phosphatase effects on autophagy and stress signaling [5,7]. Combining overexpression with phosphoproteomics helps identify the immediate downstream consequences of excess complex activity.
How EDITGENE Supports protein serine/threonine phosphatase complex Research
Researchers studying protein serine/threonine phosphatase complex-related genes often need to determine whether a candidate gene is causally involved in a phenotype or merely correlated with it. The most rigorous way to answer that question is to build isogenic cell models in which the candidate subunit is removed, mutated, tagged or overexpressed, and then to measure the downstream phosphoproteome and pathway readouts [1,3,4,5].
Contact EDITGENE today to design your custom CRISPR model for protein serine/threonine phosphatase complex research.
Frequently Asked Questions About protein serine/threonine phosphatase complex
What is GO:0008287?
GO:0008287 is the Gene Ontology cellular component term for protein serine/threonine phosphatase complex, a multi-subunit assembly that removes phosphate groups from serine or threonine residues of target proteins.
What is a protein serine/threonine phosphatase complex?
It is a complex that normally consists of a catalytic and a regulatory subunit and catalyzes removal of a phosphate group from a serine or threonine residue of a protein [2,4].
What genes are involved in protein serine/threonine phosphatase complexes?
Representative genes include PPP6C, PPP2CA, PPP1CA, PPP4C and their regulatory subunits such as PPP2R1A, PPP2R2A, PPP6R1, PPP6R2 and PPP6R3 [1,3,4,5].
What does protein phosphatase 6 do?
Protein phosphatase 6 regulates metabolic dysfunction-associated steatohepatitis via mTORC1, promotes RIPK1-dependent PANoptosis and dissociates the Beclin 1/Vps34 complex to inhibit autophagy [1,3,5].
How are serine/threonine phosphatase complexes regulated?
They are regulated by regulatory and scaffold subunits that control substrate specificity and localization, by post-translational modifications and inhibitors, and by upstream pathways such as mTORC1 [1,2,4].
Are serine/threonine phosphatases drug targets?
Yes, protein serine/threonine phosphatases have been reviewed as targets for drug development, which motivates functional studies of the corresponding complexes.
How do I study GO:0008287 in the lab?
Common approaches include phosphoproteomics, co-immunoprecipitation, autophagy and cell-death assays, and CRISPR knockout or point-mutation models [2,3,4,5].
What diseases are linked to protein serine/threonine phosphatase complexes?
Reported links include metabolic dysfunction-associated steatohepatitis, inflammatory PANoptosis, autophagy-related pathology and colorectal cancer progression under oxidative stress [1,3,5,7].
Can CRISPR knockout be used to study phosphatase complexes?
Yes, CRISPR knockout of catalytic or regulatory subunits is widely used to test requirement in metabolic, autophagy and cell-death phenotypes [1,3,5].
What is the difference between the catalytic and regulatory subunit?
The catalytic subunit performs the dephosphorylation chemistry, while the regulatory subunit controls substrate selection, activity and subcellular targeting of the complex [2,4].
Conclusion
GO:0008287, protein serine/threonine phosphatase complex, defines a modular cellular machine that reverses serine/threonine phosphorylation and thereby shapes signaling duration, pathway crosstalk and cell fate [2,4]. Its catalytic and regulatory subunits together determine substrate specificity, and its dysfunction has been connected to metabolic liver disease, inflammatory cell death, autophagy regulation and cancer progression [1,3,5,7]. Because these complexes are both biologically central and therapeutically relevant, they are a productive focus for CRISPR-based functional studies. Isogenic knockout, point-mutation, knock-in and overexpression models, combined with phosphoproteomics and screening, provide the most direct route to causal insight into GO:0008287 biology [1,3,4,5].
References
- 1. Liu Z et al.. 2025. Protein phosphatase 6 regulates metabolic dysfunction-associated steatohepatitis via the mTORC1 pathway.. J Hepatol 83(3):630-642 PMID: 39947331
- 2. Kolupaeva V. 2019. Serine-threonine protein phosphatases: Lost in translation.. Biochim Biophys Acta Mol Cell Res 1866(1):83-89 PMID: 30401537
- 3. Bynigeri RR et al.. 2024. The protein phosphatase PP6 promotes RIPK1-dependent PANoptosis.. BMC Biol 22(1):122 PMID: 38807188
- 4. Kokot T et al.. 2022. Emerging insights into serine/threonine-specific phosphoprotein phosphatase function and selectivity.. J Cell Sci 135(19) PMID: 36205606
- 5. Fujiwara N et al.. 2021. Protein phosphatase 6 dissociates the Beclin 1/Vps34 complex and inhibits autophagy.. Biochem Biophys Res Commun 552:191-195 PMID: 33751937
- 6. Heim A et al.. 2017. Regulation of Cell Division.. Adv Exp Med Biol 953:83-116 PMID: 27975271
- 7. Wang S et al.. 2025. ROS-induced cytosolic release of mitochondrial PGAM5 promotes colorectal cancer progression by interacting with MST3.. Nat Commun 16(1):1406 PMID: 39915446
- 8. McConnell JL et al.. 2009. Targeting protein serine/threonine phosphatases for drug development.. Mol Pharmacol 75(6):1249-61 PMID: 19299564
